Dyne Therapeutics (NASDAQ:DYN) is a clinical-stage biotechnology company focused on the development of precision genetic therapies for serious rare neuromuscular diseases. Established in 2019 as a spin-out from Flagship Pioneering, Dyne leverages proprietary delivery technology to enhance the uptake and targeting of oligonucleotide therapeutics. The company’s mission is to create potentially transformative treatments for patients affected by diseases such as Duchenne muscular dystrophy, myotonic dystrophy type 1, and limb-girdle muscular dystrophies, which historically have had limited therapeutic options.
At the core of Dyne’s strategy is its FORCE (Facilitated Oligonucleotide Chemistries and Enhanced Delivery) platform, designed to improve cellular delivery of oligonucleotides across muscle and other challenging tissues. This platform enables the company to optimize stability, tissue specificity, and pharmacological activity of its candidates. Dyne’s lead program, DYST-ON, is a next-generation antisense oligonucleotide for Duchenne muscular dystrophy currently in clinical development, while MYO-101 for myotonic dystrophy type 1 and additional programs targeting various limb-girdle muscular dystrophy subtypes are advancing in preclinical and early clinical stages.
Dyne maintains collaborations with several major pharmaceutical and biotechnology partners to broaden its research capabilities and accelerate clinical development. The company has entered strategic alliances aimed at co-developing next-generation oligonucleotide drugs, drawing upon the global expertise of industry leaders. These partnerships are intended to leverage shared resources for manufacturing, regulatory planning, and commercialization, positioning Dyne to bring potential therapies to patients more efficiently.
Headquartered in Cambridge, Massachusetts, Dyne Therapeutics serves both U.S. and international patient communities through ongoing clinical trials and research activities. Under the leadership of Founder and Chief Executive Officer Edward Kaye, Ph.D., the management team combines deep expertise in molecular biology, drug delivery, and rare disease clinical development. With a commitment to scientific innovation and patient-centric research, Dyne is advancing a pipeline of differentiated therapies that aim to address unmet needs in neuromuscular disease treatment.
